Active ingredient: Propofol - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

• Anesthetics, Intravenous
• Anticonvulsants
• Antiemetics
• Free Radical Scavengers
• Hypnotics and Sedatives

Dosage Forms

• Emulsion
• Liquid
• Solution

Brands / Synonyms

Diisopropylphenol; Diprivan; Disoprivan; Disoprofol; Rapinovet

Indications

Used for both induction and/or maintenance of anesthesia.

Pharmacology

Propofol a sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of propofol produces hypnosis rapidly with minimal excitation, usually within 40 seconds from the start of an injection (the time for one arm-brain circulation).

Mechanism of Action

The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid(GABA) through GABA-A receptors.

Absorption

Not Available

Toxicity

Not Available

Biotrnasformation / Drug Metabolism

Hepatic

Contraindications

DIPRIVAN Injectable Emulsion is contraindicated in patients with a known hypersensitivity to DIPRIVAN Injectable Emulsion or its components, or when general anesthesia or sedation are contraindicated.

Drug Interactions

The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of DIPRIVAN Injectable Emulsion and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output.

During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. These inhalational agents can also be expected to increase the anesthetic or sedative and cardiorespiratory effects of DIPRIVAN Injectable Emulsion.

DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).

No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.